Browse medicines
Some records contain detailed evidence; others currently contain only basic identity and regulatory information. Reviewed conclusions appear only when they are available for a specific use and group of people.
Medicine type
Approval status
AllApproved in the United States (FDA)Approved in the European Union (EMA)In Phase 3 testingIn Phase 2 testingUsed in a way not covered by an approval, or made by a compounding pharmacyDietary supplement; not FDA-approved as a medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Laboratory or animal-stage researchControlled substance; no approved US useWithdrawn from the market
Amount of information
Showing 1–5 of 5 records
Eteplirsen (Exondys 51)
Gene-silencing medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Detailed recordUse listed on the medicine record
Duchenne Muscular Dystrophy (exon 51 skipping)
Golodirsen (Vyondys 53)
Gene-silencing medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Detailed recordUse listed on the medicine record
Duchenne Muscular Dystrophy (exon 53 skipping)
Tofersen (Qalsody)
Gene-silencing medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Detailed recordUse listed on the medicine record
SOD1 Amyotrophic Lateral Sclerosis (ALS)
Casimersen (Amondys 45)
Gene-silencing medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Detailed recordUse listed on the medicine record
Duchenne Muscular Dystrophy (exon 45 skipping)
Viltolarsen (Viltepso)
Gene-silencing medicineFDA accelerated approval (based on an earlier result expected to predict benefit; follow-up evidence may be required)Detailed recordUse listed on the medicine record
Duchenne Muscular Dystrophy (exon 53 skipping)